Category: Regulations
-
Infographic – U.S. Falling Way Behind on 5G
The success of mobile devices depends on their underlying technologies, with the next generation of mobile standards known as 5G in the queue.
-
FDA Approves RNA-Interference Nerve Disease Therapy
A treatment that silences the actions of RNA and reverses damage to nerves from a rare inherited neurological disease was approved by the Food and Drug Administration.
-
Despite Crisis, U.S. Prescription Opioid Use Remains High
A review of insurance claims over a 10-year period shows prescription opioid use in the U.S. remains at a high level with few signs of declining, despite repeated and vocal public concerns about these drugs.
-
Trial Shows Antibiotic More Effective Against Crohn’s Disease
Early results from a clinical trial show an experimental antibiotic drug helps more people achieve remission of their Crohn’s disease for longer periods than a similar group given a placebo.
-
Technique Assessed for Comparing Effectiveness Between Drugs
An academic-industry research team validated a statistical technique to evaluate the effectiveness of different drugs treating the same disease, without conducting separate head-to-head clinical trials.
-
Infographic – U.S. Smoking Rate Hits New Low
These data show fewer than 1 in 6 Americans, or 16 percent, smoked a cigarette in the past week.
-
More Damage Detected from Crispr-Cas9 Edits
A genetics lab in the U.K. revealed that a leading technique for editing genomes produces more unwanted damage to the edited genomes than previously understood.
-
FDA Issues Draft Gene Therapy Regulatory Guidance
FDA issued a series of draft documents spelling out its processes for reviewing gene therapies for three types of diseases, as well as producing and testing these treatments.
-
Apps Seen Over-Diagnosing Mental Health Conditions
A study of leading mobile apps for mental health indicates many apps promote their use with misleading guidance to individuals on the extent and seriousness of psychological conditions.
-
FDA Reviewers Found Accepting Industry Payments After Drug Approvals
A new report finds a large percentage of panel members that review drug applications for the Food and Drug Administration accept payments and other rewards from companies after their drugs are approved.